A plan for sustainable funding for US biomedical research

[1] Rescuing US biomedical research from its systemic flaws [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (16) : 5773 - 5777

[2] American Society of Biochemistry and Molecular Biology, 2013, SURV UNL POT VAN OPP

[3] Anthony E., 2014, NIH BUDGET ESTIMATES

[4] Phase II and Phase III attrition rates 2011-2012 [J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (08) : 568 - 568

[5] Battelle Technology Partnership Practice and PhRMA, 2011, US BIOPH SECT EC CON

[6] Bourgoin A.Fischer, 2013, WHITE PAPER OUTLOOK

[7] Balancing Innovation, Access, and Profits -- Market Exclusivity for Biologics. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (20) : 1917 - 1919

[8] Holdren J.P., 2012, Report to the president - transformation and opportunity: the future of the U.S. research enterprise

[9] Hornig D., 2013, IS PATENT CLIFF LETH

[10] IMS Institute for Healthcare Informatics, 2013, MED US SHIFT COSTS H

[1] Rescuing US biomedical research from its systemic flaws [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (16) : 5773 - 5777

[2] American Society of Biochemistry and Molecular Biology, 2013, SURV UNL POT VAN OPP

[3] Anthony E., 2014, NIH BUDGET ESTIMATES

[4] Phase II and Phase III attrition rates 2011-2012 [J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (08) : 568 - 568

[5] Battelle Technology Partnership Practice and PhRMA, 2011, US BIOPH SECT EC CON

[6] Bourgoin A.Fischer, 2013, WHITE PAPER OUTLOOK

[7] Balancing Innovation, Access, and Profits -- Market Exclusivity for Biologics. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (20) : 1917 - 1919

[8] Holdren J.P., 2012, Report to the president - transformation and opportunity: the future of the U.S. research enterprise

[9] Hornig D., 2013, IS PATENT CLIFF LETH

[10] IMS Institute for Healthcare Informatics, 2013, MED US SHIFT COSTS H